UroGen Pharma Ltd. Number of Reportable Segments
UroGen Pharma Ltd. (URGN) reported Number of Reportable Segments of 100.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-05
- UroGen Pharma Ltd. number of reportable segments for the quarter ending 2026-03-31 was 100.00%.
- UroGen Pharma Ltd. number of reportable segments for fiscal 2025 was 100.00%, a 0.00% change from fiscal 2024.
- UroGen Pharma Ltd. number of reportable segments for fiscal 2024 was 100.00%.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 100.00% 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 100.00% 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | 100.00% 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 100.00% 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | 100.00% 10-K · filed 2025-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |